IP Library › Patent Application 12852681

Patent Application

App. No. 12/852,681

INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 12/852,681

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated, with a variety of compounds, including Wnt inhibitor compounds. More particularly, it concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components.

Claims (129)

1 . A method of treating a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound having a structure of Formula I, or a pharmaceutically acceptable salt or pro-drug thereof:

wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 and R 8 are independently selected from the group consisting of H, C 1-9 alkyl, halide, —CF 3 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 , —(C 1-9 alkyl) n heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 )S(═O)R 10 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n NR 9 C(═O)OR 9 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n OC(═O)N(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

R 3 is selected from the group consisting of —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 , —(C 1-9 alkyl) n heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 )S(═O)R 10 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n NR 9 C(═O)OR 9 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n OC(═O)N(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

alternatively, one of each R 1 and R 2 , R 2 and R 3 , R 3 and R 4 , R 5 and R 6 , R 6 and R 7 or R 7 and R 8 are taken together to form a ring which is selected from the group consisting of aryl, heteroaryl,

wherein each bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond;

each R 9 is independently selected from the group consisting of H, —C 1-9 alkyl, —CF 3 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 and —(C 1-9 alkyl) n heteroarylR 12 ;

each R 10 is independently selected from the group consisting of —C 1-9 alkyl, —CF 3 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 and —(C 1-9 alkyl) n heteroarylR 12 ;

each R 11 is independently selected from the group consisting of CN, —OR 9 and R 9 ;

each R 12 is 1-5 substituents each selected from the group consisting of H, —C 1-9 alkyl, -alkylaminoalkyl, halide, —CF 3 , carbocyclylR 12 , heterocyclylR 12 , arylR 12 , heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n NR 9 C(═O)OR 9 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n OC(═O)N(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

R 13 and R 14 are independently selected from the group consisting of H, C 1-9 alkyl, halide, —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 , —(C 1-9 alkyl) n heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

alternatively, R 13 and R 14 are taken together to form a ring which is selected from the group consisting of benzene and pyridine;

each A is independently selected from O, S and NR 11 ; and

each n is 0 or 1.

2 . The method of claim 1 wherein n is 0.

3 . The method of claim 1 wherein n is 1.

4 . The method of claim 1 wherein A is O.

5 . The method of claim 1 wherein R 1 , R 2 and R 4 are H and R 3 is independently selected from the group consisting of —(C 1-9 alkyl) n arylR 12 , —(C 1-9 alkyl) n heteroarylR 12 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n NR 9 C(═O)OR 9 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n OC(═O)N(R 9 ) 2 , —CN, n is 0 and A is O.

6 . The method of claim 5 wherein R 3 is arylR 12 .

7 . The method of claim 5 wherein R 3 is heteroarylR 12 .

8 . The method of claim 5 wherein R 3 is —N(R 9 )C(═O)N(R 9 ) 2 .

9 . The method of claim 5 wherein R 3 is —NR 9 C(═O)OR 9 .

10 . The method of claim 5 wherein R 3 is —C(═O)N(R 9 ) 2 .

11 . The method of claim 5 wherein R 3 is —N(R 9 )C(═O)R 9 .

12 . The method of claim 5 wherein R 3 is —OC(═O)N(R 9 ) 2 .

13 . The method of claim 5 wherein R 3 is —CN.

14 . The method of claim 7 wherein the heteroarylR 12 is a pyridine and R 12 is selected from the group consisting of -alkylaminoalkyl, —C(═O)NHR 9 and —NHC(═O)R 9 .

15 . The method of claim 10 wherein R 3 is —C(═O)NHR 9 and R 9 is selected from the group consisting of —C 1-9 alkyl and —(C 1-9 alkyl) n heterocyclylR 12 .

16 . The method of claim 1 , wherein the compound has a structure selected from the group consisting of:

or a pharmaceutically acceptable salt or prodrug thereof.

17 . A method of treating a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound having a structure of Formula II, or a pharmaceutically acceptable salt or pro-drug thereof:

alternatively, one of each R 1 and R 2 , R 2 and R 15 , R 15 and R 4 , R 5 and R 6 , R 6 and R 7 or R 7 and R 8 are taken together to form a ring which is selected from the group consisting of aryl, heteroaryl,

wherein each bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond;

each R 11 is independently selected from the group consisting of CN, —OR 9 and R 9 ;

each R 12 is 1-5 substituents each selected from the group consisting of H, C 1-9 alkyl, -alkylaminoalkyl, halide, —CF 3 , carbocyclylR 12 , heterocyclylR 12 , arylR 12 , heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n NR 9 C(═O)OR 9 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n OC(═O)N(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

alternatively, R 13 and R 14 are taken together to form a ring which is selected from the group consisting of benzene and pyridine;

each R 15 is selected from the group consisting of -carbocyclylR 16 , —(C 1-9 alkyl)carbocyclylR 12 , -heterocyclylR 16 , —(C 1-9 alkyl)heterocyclylR 12 , -arylR 16 , —(C 1-9 alkyl)arylR 12 , -heteroarylR 16 , —(C 1-9 alkyl)heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl)N(R 9 )S(═O)R 10 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n NR 9 C(═O)OR 9 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

each R 16 is 1-5 substituents each selected from the group consisting of H, C 1-9 alkyl, halide, —CF 3 , carbocyclylR 12 , heterocyclylR 12 , arylR 12 , heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl)N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —N(R 17 ) 2 , —(C 1-9 alkyl)N(R 9 ) 2 , —NR 9 C(═O)N(R 17 ) 2 , —(C 1-9 alkyl)N(R 9 )C(=A)N(R 9 ) 2 , —C(═O)NR 9 R 18 , —(C 1-9 alkyl)C(=A)N(R 9 ) 2 , —(C 1-9 alkyl)NR 9 C(═O)OR 9 , —(C 1-9 alkyl)N(R 9 )C(=A)R 9 , —(C 1-9 alkyl)OC(═O)N(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl)C(=A)R 9 ;

each R 17 is H, —(C 1-9 alkyl) n carbocyclyl, —(C 1-9 alkyl) n heterocyclyl, —(C 1-9 alkyl) n aryl and —(C 1-9 alkyl) n heteroaryl;

each R 18 is independently selected from the group consisting of H, —C 1-9 alkyl, —CF 3 , -carbocyclylR 12 , —(C 1-9 alkyl) n arylR 12 and —(C 1-9 alkyl) n heteroarylR 12 ;

each A is independently selected from O, S and NR 11 ;

Y 1 , Y 2 , Y 3 and Y 4 are independently selected from the group consisting of carbon and nitrogen with the proviso that at least one of Y 1 , Y 2 , Y 3 and Y 4 are nitrogen; wherein

if Y 1 is nitrogen then R 5 is absent;

if Y 2 is nitrogen then R 6 is absent;

if Y 3 is nitrogen then R 7 is absent;

if Y 4 is nitrogen then R 8 is absent; and

each n is 0 or 1.

18 . The method of claim 17 wherein n is 0.

19 . The method of claim 17 wherein n is 1.

20 . The method of claim 17 wherein A is O.

21 . The method of claim 17 wherein R 1 , R 2 and R 4 are H and R 15 is independently selected from the group consisting of -heteroarylR 16 , -arylR 16 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n NR 9 C(═O)OR 9 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , n is 0 and A is O.

22 . The method of claim 21 wherein R 15 is arylR 16 .

23 . The method of claim 21 wherein R 15 is heteroarylR 16 .

24 . The method of claim 21 wherein R 15 is —N(R 9 )C(═O)N(R 9 ) 2 .

25 . The method of claim 21 wherein R 15 is —NR 9 C(═O)OR 9 .

26 . The method of claim 21 wherein R 15 is —C(═O)N(R 9 ) 2 .

27 . The method of claim 21 wherein R 15 is —N(R 9 )C(═O)R 9 .

28 . The method of claim 23 wherein the heteroarylR 16 is a pyridine and R 16 is selected from the group consisting of —(C 1-9 alkyl)NHR 9 and —C(═O)NHR 18 .

29 . The method of claim 26 wherein R 15 is —C(═O)NHR 9 and R 9 is selected from the group consisting of —C 1-9 alkyl and —(C 1-9 alkyl) n heterocyclylR 12 .

30 . The method of claim 17 , wherein the compound has the structure set forth below, or a pharmaceutically acceptable salt or prodrug thereof:

31 . A method of treating a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound having a structure of Formula III, or a pharmaceutically acceptable salt or pro-drug thereof:

wherein R 1 , R 2 , R 4 , R 5 and R 6 are independently selected from the group consisting of H, C 1-9 alkyl, halide, —CF 3 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 , —(C 1-9 alkyl) n heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 )S(═O)R 10 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n NR 9 C(═O)OR 9 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n OC(═O)N(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

each R 9 is independently selected from the group consisting of H, —C 1-9 alkyl, —(C 1-9 alkyl)OR 9 , —(C 1-9 alkyl)N(R 9 ) 2 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 and —(C 1-9 alkyl) n heteroarylR 12 ;

each R 10 is independently selected from the group consisting of —C 1-9 alkyl, —(C 1-9 alkyl)OR 9 , —(C 1-9 alkyl)N(R 9 ) 2 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 and —(C 1-9 alkyl) n heteroarylR 12 ;

alternatively, R 9 and R 10 are taken together to form a 3-10 membered heterocyclyl ring;

each R 11 is independently selected from the group consisting of CN, —OR 9 and R 9 ;

each A is independently selected from O, S and NR 11 ; and

each n is 0 or 1.

32 . The method of claim 31 wherein n is 0.

33 . The method of claim 31 wherein n is 1.

34 . The method of claim 31 wherein A is O.

35 . The method of claim 31 wherein R 1 , R 2 , R 4 , R 5 and R 6 are independently selected from the group consisting of independently selected from the group consisting of H, C 1-9 alkyl, halide, —CF 3 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n N(R 9 ) 2 , —CN and —(C 1-9 alkyl) n C(=A)R 9 .

36 . The method of claim 31 wherein R 9 is H.

37 . The method of claim 31 wherein R 10 is —C 1-9 alkyl.

38 . The method of claim 31 wherein R 10 is —(C 1-9 alkyl)OR 9 .

39 . The method of claim 31 wherein R 10 is —(C 1-9 alkyl)N(R 9 ) 2 .

40 . The method of claim 31 wherein R 10 is —(C 1-9 alkyl)carbocyclylR 12 .

41 . The method of claim 31 wherein R 10 is —(C 1-9 alkyl)heterocyclylR 12 .

42 . The method of claim 31 wherein R 10 is —(C 1-9 alkyl)arylR 12 .

43 . The method of claim 31 wherein R 10 is —(C 1-9 alkyl)heteroarylR 12 .

44 . The method of claim 31 wherein R 9 and R 10 are taken together to form a 6-membered heterocyclyl ring.

45 . The method of claim 31 wherein R 9 and R 10 are taken together to form a 5-membered heterocyclyl ring.

46 . The method of claim 31 , wherein the compound has a structure selected from the group consisting of:

or a pharmaceutically acceptable salt or prodrug thereof.

47 . A method of treating a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound having a structure of Formula IV, or a pharmaceutically acceptable salt or pro-drug thereof:

wherein each R 9 is independently selected from the group consisting of H, —C 1-9 alkyl, —CF 3 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 and —(C 1-9 alkyl) n heteroarylR 12 ;

each R 11 is independently selected from the group consisting of CN, —OR 9 and R 9 ;

R 19 is independently selected from the group consisting of C 1-9 alkyl, —OR 9 , amino, —S(═O)R 10 , —SO 2 R 9 , —N(R 9 )S(═O)R 10 , —N(R 9 )SO 2 R 9 , —SO 2 N(R 9 ) 2 , —N(R 9 ) 2 , —N(R 9 )C(═O)N(R 9 ) 2 , —NR 9 C(═O)OR 9 , —C(═O)N(R 9 ) 2 , —N(R 9 )C(═O)R 9 , —OC(═O)N(R 9 ) 2 , —CO 2 R 9 and —C(═O)R 9 ;

R 20 is independently selected from the group consisting of arylR 12 and heteroarylR 12 ;

each A is independently selected from O, S and NR 11 ; and

each n is 0 or 1.

48 . The method of claim 47 wherein n is 0.

49 . The method of claim 47 wherein n is 1.

50 . The method of claim 47 wherein A is O.

51 . The method of claim 47 wherein R 19 is —C(═O)N(R 9 ) 2 .

52 . The method of claim 47 wherein R 19 is —C(═O)NH 2 .

53 . The method of claim 47 wherein R 19 is —C(═O)NHR 9 .

54 . The method of claim 47 wherein R 20 is arylR 12 .

55 . The method of claim 47 wherein R 20 is heterocyclylR 12 .

56 . The method of claim 47 , wherein the compound has a structure selected from the group consisting of:

or a pharmaceutically acceptable salt or prodrug thereof.

57 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of the formulas I, II, III, or IV, as set forth herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient:

58 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is cancer.

59 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is diabetic retinopathy.

60 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is neovascular glaucoma.

61 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is rheumatoid arthritis.

62 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is psoriasis.

63 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is a mycotic or viral infection.

64 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is osteochondrodysplasia.

65 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is Alzheimer's disease.

66 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is osteoarthritis.

67 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is chosen from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome and Rett syndrome.

68 . The method according to any of the claim 1 , 17 , 31 or 47 , wherein the patient is a human.

69 . The method of claim 58 , wherein the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer leukemia, lymphoma, sarcoma and ovarian cancer.

70 . The method according to any of the claim 1 , 17 , 31 or 47 , wherein the compound inhibits one or more proteins in the Wnt pathway.

71 . The method according to any of the claim 1 , 17 , 31 or 47 , wherein the compound inhibits signaling induced by one or more Wnt proteins.

72 . The method of claim 71 , wherein the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4. WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

73 . The method according to any of the claim 1 , 17 , 31 or 47 , wherein the compound inhibits a kinase activity.

74 . The method of claim 73 , wherein the kinase activity mediates a disease or disorder comprising tumor growth, cell proliferation, or angiogenesis.

75 . The method of claim 74 , wherein the protein kinase is from the CDK, VEGF, CLK, HIPK, Abl, JAK or CHK families of kinases.

76 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the disorder or disease is associated with aberrant cellular proliferation.

77 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the method prevents or reduces angiogenesis in a patient.

78 . A method according to any of the claim 1 , 17 , 31 or 47 , wherein the method prevents or reduces abnormal cellular proliferation in a patient.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2012

From: EPITHERIX, LLC

To: SAMUMED, LLC

Reel/Frame 028442/0355 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2010

From: HOOD, JOHN; KC, SUNIL KUMAR

To: EPITHERIX, LLC

Reel/Frame 024875/0113 →